More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement.
Maya Desai
Advertisement
Articles by Maya Desai
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
While COVID-19 has shifted the rules of the healthcare industry, research shows there was already progress on changes being made for how pharma companies are launching products.
Advertisement
Latest Updated Articles
- New Standards for First-to-Launch Players
Published: September 14th 2020 | Updated:
- Research Reveals New Launch Standards for First-to-Launch Pharma and Biotech Companies in the U.S.
Published: June 26th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
2
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
3
FDA Announces New Biosimilar-Targeted Draft Guidance
4
Lilly Forms Partnership with NVIDIA to Create AI Supercomputer
5
